The authors report on 2 patients with chronic arterial occlusion in whom the intravenous administration of the glycosaminoglycan compound FPFD 101 was markedly effective. One patient suffered from thromboembolic episodes of the left hand, and the other had peripheral circulatory impairment related to colla gen disease. In these patients, the oral administration of anticoagulants and antiplatelet agents in combination with intravenous infusion of prostaglandin E1 was not adequately effective. However, the addition of intravenous injection of FPFD 101 resulted in a marked improvement in their symptoms. FPFD 101, which has an anticoagulant effect and also inhibits platelet aggregation, seems to be useful for the treatment and prevention of chronic arterial occlusion when combined with drugs such as anticoagulants, antiplatelet agents, and vasodila tors.
Get full access to this article
View all access options for this article.
References
1.
Hirai M., Nangi M., Nakayama R.: Evaluation of drip infusion of PGE1 in arterial occlusive diseases in the lower extremities. J Jpm Coll Angiol24:1167-1171, 1984 (abstract in Japanese).
2.
Hirai M., Nakayama R.: PGE, administration and steal phenomenon in ischemic limbs. Jpm. J. ofCircul. Res.8:153-160, 1985 (in Japanese).
3.
Wight TN: Cell biology of arterial proteoglycans. Arteriosclerosis9:1-20, 1989.
4.
Busch C., Owen WG: Identification in vitro of an endothelial cell surface cofactor for antithrombin III. Parallel studies with isolated perfused rat hearts and microcarrier cultures of bovine endothelium. J Clin Invest69:726-729, 1982.
5.
Shimada K., Ozawa T.: Modulation of glycosaminoglycan production and antithrombin III binding by cultured aortic endothelial cells treated with 4-methylumbelliferyl-β-D-xyloside . Arteriosclerosis7:627-638, 1987.
6.
Czapek EE, Kwaan HC, Szczecinski M.: The effect of a sulfated polysaccharide on antithrombin III. J Lab Clin Med95:783-790, 1980.
7.
Vinazzer H., Hass S., Stemberger A.: Influence on the clotting mechanism of sodium pentosan polysulfate (SP 54) in comparison to commercial beef lung sodium heparin. Thrombosis Res20:57-68, 1980.
8.
Bergqvist D. , Nilsson IM: A sulfated polysaccharide— the effects in vivo and in vitro on the heamostatic system in healthy volunteers. Thrombosis Res23:309-315, 1981.
9.
Coccheri S., De Rosa N., Pelusi G., et al: The effect of some fibrinolytically active sulfated polysaccharides and a polydesoxynucleotide on the inhibition of factor Xa. Prog Chem Fibrinolysis Thrombolysis4:61-67, 1979.
10.
Klein K., Sinzinger H., Silberbaur K., et al: Influence of proteoglycans (PG) and glycosaminoglycans (GAG) on ADP-, collagen- and thrombin-induced platelet aggregation. Artery8:410-415, 1980.
11.
Segawa J., Kawashima T., Yashiro A., et al: Acute effects of intravenous administration of glycosaminoglycans compound (FPFD 101) on healthy volunteers. J Jpn Atherosclerosis Soc16:871, 1988 (abstract in Japanese).
